Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue

Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.79, $0.26 better than the analyst estimate of $3.53. Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.3 billion.

GUIDANCE:

Vertex Pharma sees Q1 2023 revenue of $9.55-9.7 billion, versus the consensus of $9.6 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance